Skip to main content
Medical information Clinical review pending

Genetic Testing

Sox17 Gene Vesicoureteral Reflux Type 3 Genetic Test

This genetic test analyzes the Sox17 gene to identify predispositions to vesicoureteral reflux (VUR), a condition where urine flows backward from the bladder to the kidneys. It uses Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No specific preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Sox17 Gene Vesicoureteral Reflux Type 3 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of vesicoureteral reflux (VUR)
  • ✓Recurrent urinary tract infections (UTIs)
  • ✓Diagnosis of renal complications potentially related to VUR
  • ✓Understanding genetic risk factors for VUR
02

In plain language

What this test helps you understand

Identifies genetic variations in the Sox17 gene associated with vesicoureteral reflux (VUR), aiding in understanding predisposition and informing management strategies.
The Sox17 Gene Vesicoureteral Reflux Type 3 NGS Genetic DNA Test is a diagnostic tool used to identify genetic factors associated with vesicoureteral reflux (VUR). VUR occurs when urine flows backward from the bladder into the ureters or kidneys, potentially leading to kidney infections and damage. Understanding the genetic basis of VUR can help with early diagnosis and management.

This test utilizes Next-Generation Sequencing (NGS) technology to examine the Sox17 gene. Variations in this gene have been linked to the development of VUR. Identifying these variations can provide valuable information about an individual's risk for developing the condition.

Consider this test if you have a family history of VUR, experience recurrent urinary tract infections, or have been diagnosed with kidney complications potentially related to VUR.

Taking this test can lead to early identification of genetic risks, inform treatment decisions, and help families understand their risk factors. Results are typically available within 3 to 4 weeks. A genetic counseling session is recommended to help interpret the results and discuss implications for family members.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific preparation is required for this test. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the Sox17 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific variations in the Sox17 gene. It does not detect all possible causes of VUR. A negative result does not completely rule out a genetic predisposition. Interpretation requires clinical correlation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

VUR is a condition where urine flows backward from the bladder up towards the kidneys. This can increase the risk of kidney infections and damage.
This test looks for specific genetic variations (mutations) in the Sox17 gene, which is associated with an increased risk of developing VUR.
Individuals with a family history of VUR, those experiencing recurrent UTIs, or patients with kidney problems potentially linked to VUR may benefit from this test.
Results are generally available within 3 to 4 weeks. Please confirm the current turnaround time with the laboratory.
A genetic counseling session is recommended to help understand the test results and their implications for you and your family. Please inquire about availability.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp